EVOVEST GLOBAL EQUITY ETF UNITS CAD
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 5.1K
- Market Cap
- $1.3B
- Website
- http://evotec.com
- Introduction
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Sernova Biotherapeutics Chairman Ross Haghighat Resigns as Company Advances Type 1 Diabetes Cell Therapy
Sernova Biotherapeutics announced the resignation of Chairman Ross Haghighat, effective May 24, 2025, with the board accepting his departure and thanking him for his leadership.
Peptone and Evotec Form Strategic Alliance to Develop Novel Therapeutics Targeting Intrinsically Disordered Proteins
Peptone and Evotec have established a strategic partnership to accelerate the development of small molecule therapeutics targeting intrinsically disordered proteins (IDPs) across multiple therapeutic areas, including oncology and immunology.
Gates Foundation Awards Evotec $2.5M Grant to Advance Next-Generation Tuberculosis Treatments
The Gates Foundation has awarded Evotec a $2.5 million grant to support the development of next-generation tuberculosis treatment regimens, building on their five-year partnership.
Evotec and Bristol Myers Squibb Achieve Major Milestone in Molecular Glue Degrader Collaboration, Triggering $75M Payment
Evotec SE announced significant progress in its strategic protein degradation collaboration with Bristol Myers Squibb, triggering performance-based payments totaling $75 million.
Oncodesign Services Appoints Dr. Aidan Synnott as CEO to Strengthen Drug Discovery Partnerships
• Dr. Aidan Synnott, former Corporate VP at Charles River Laboratories with over 20 years of biomedical research experience, has been appointed CEO of Oncodesign Services to enhance client collaboration and scientific quality. • The appointment marks a significant milestone in Oncodesign's transformation following its acquisition of ZoBio and expansion into molecular radiotherapy and protein sciences. • Synnott will focus on aligning the company's structure with drug discovery priorities, integrating operations across Europe and North America, and creating a unified offering to accelerate client programs.
Sernova's Cell Pouch Bio-Hybrid Organ Shows Promise in Type 1 Diabetes Clinical Trial
Sernova Biotherapeutics' Phase 1/2 clinical trial for its Cell Pouch Bio-hybrid Organ has received DSMB approval to enroll the final patient in Cohort B and advance to Cohort C in H2 2025.
Roche Expands Molecular Glue Portfolio with $2 Billion Monte Rosa Partnership
Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases.
Evotec Receives $20 Million from Bristol Myers Squibb for Neurodegenerative Disease Program Advancement
Evotec has achieved a significant milestone in its neuroscience collaboration with Bristol Myers Squibb, triggering a $20 million research payment to advance a promising pre-clinical neurodegeneration program.
Enterprise Therapeutics' ETD001 Shows Promise in Cystic Fibrosis Phase 2 Trial
Enterprise Therapeutics' ETD001, an inhaled ENaC blocker, is currently in Phase 2 clinical trials to assess its impact on lung function in cystic fibrosis patients.
Halozyme Abandons Evotec Acquisition, Neurogene Trial Faces Setback, Argenx Advances Myositis Program, and Kyowa Kirin Licenses Kura Oncology's Leukemia Drug
Halozyme withdrew its $2.1 billion offer to acquire Evotec after the latter declined to engage in acquisition talks, despite Halozyme's repeated attempts to initiate discussions.